Evaluation of economic burden with biologic treatments in Crohn's disease patients: A mirror image study using an insurance database in Japan.
Biologics are recommended in Japan to treat moderate to severe Crohn's Disease (CD). Although CD is associated with high direct costs in Japan, updated information after ustekinumab's approval is unavailable. We aimed to evaluate the healthcare resource utilization (HRU) and associated dir...
Saved in:
Main Authors: | , , , |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/eed567d2c6054272be60fc9f1dab3d8e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|